Pharmacologic optimization of antibiotics for Gram-negative infections.

摘要: PURPOSE OF REVIEW Antimicrobial resistance among Gram-negative organisms is a rapidly escalating global challenge. Pharmacologic dose optimization based on pharmacokinetic/pharmacodynamic principles essential for managing infections. High-risk patient populations may receive nonoptimized antimicrobial dosing because pf physiologic changes in acute illness and/or medical interventions. The purpose of this review to discuss opportunities pharmacologic new agents and highlight that are often associated with poor drug exposure profiles. RECENT FINDINGS Dose the novel β-lactam-β-lactamase inhibitor combinations has been evaluated through optimizing at site infection, evaluating target attainment both β-lactam β-lactamase-inhibitor critically ill patients, prevent development resistance. Plazomicin, aminoglycoside, pharmacodynamic potential via therapeutic monitoring nomogram-based dosing. Recent studies have adequacy varying degrees renal function specifically kidney injury, continuous replacement therapy (CRRT), augmented clearance (ARC). SUMMARY application fundamental required optimize antimicrobials treatment serious Exposure pharmacokinetics exposures all considerations improve microbiologic clinical outcomes. Therapeutic be needed high-risk patients.